Method to engineer transplantable human tissues
AssigneeThe Regents of the University of California
InventorsKun Zhang, Yan Wu, Amir Dailamy, Prashant Mali, Daniella McDonald, Udit Parekh, Michael Hu
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods, polynucleotides, vectors, viral particles, cells, and systems or the engineering of human tissues. One aspect of the disclosure relates to using lineage-specific miRNA binding molecules to bias tissue lineage. Another aspect of the disclosure relates to using lineage-specific transcription factor overexpression to bias tissue lineage.
Claims16
An in vitro or ex vivo method of producing a lineage-specific target cell population from a teratoma comprising a lineage-specific miRNA of the target cell population, the method comprising:
- contacting the teratoma with a lineage-specific miRNA binding polynucleotide comprising a lineage-specific miRNA binding site specific to the lineage-specific miRNA of the target cell population operably linked to a polynucleotide encoding a prodrug modification polypeptide;
- and
- contacting the teratoma with a prodrug;
- thereby producing the lineage-specific target cell population.
A method of producing a lineage-specific target cell population from a teratoma comprising:
- administering a prodrug to a teratoma comprising a lineage-specific miRNA-binding polynucleotide,
- wherein the lineage specific miRNA binding polynucleotide comprises a lineage-specific miRNA-binding site operably linked to a polynucleotide encoding a prodrug modification polypeptide, and
- wherein the teratoma comprises at least one cell type that expresses a lineage-specific miRNA that binds to the lineage-specific miRNA binding site;
- overexpressing in the teratoma at least one transcription factor capable of biasing differentiation of the teratoma;
- and
- exposing the teratoma to a growth medium, wherein the growth medium is compatible with biasing differentiation of the teratoma;
- and
- thereby producing the lineage-specific target cell population;
- optionally wherein the teratoma is derived from human pluripotent stem cells (hPSCs), or an ex vivo tissue engineered construct.
Dependencies are inferred from the claim text.